Today's Edition
ABU DHABI (WAM)
In a significant advancement for cancer prevention and care, the Abu Dhabi Public Health Centre (ADPHC), in partnership with M42, has introduced a non-invasive blood-based cancer screening for colorectal cancer, termed as liquid biopsy.
This innovative test expands on the latest advancements in Abu Dhabi’s health sector, reinforcing its commitment to providing world-class oncology diagnosis and care, and promoting preventative health measures.
The liquid biopsy test for colorectal cancer complements, but does not replace colonoscopy, which is the gold standard for colorectal cancer diagnosis.
It plays a crucial role in risk stratification and early detection of tumours or precancerous growths in the colon.
By enhancing early detection capabilities, this test marks a significant advancement in the fight against colorectal cancer.
Acting Director General of ADPHC, Dr. Ahmed AlKhazraji, commented, “Abu Dhabi is taking a crucial step in prioritising community health by promoting early cancer detection. The introduction of an innovative and non-invasive test like liquid biopsy provides a more accessible and comfortable screening option for patients, reducing barriers and encouraging greater participation in regular screenings. This initiative supports Abu Dhabi's commitment to population health by incorporating advanced, personalised screening technologies focused on precision and preventive care, and making regular health screenings a standardised practice for the population.”
The liquid biopsy will be provided as part of the IFHAS comprehensive health screening programme and is available at key healthcare centres of Ambulatory Healthcare Services (AHS) and M42 across Abu Dhabi, Al Ain, and the Al Dhafra Region.
Commenting on the launch of the Shield Test, Dr. Fahed Al Marzooqi, Deputy COO of M42, said, “This step will help boost early detection for colorectal cancer in Abu Dhabi and tackle one of the leading causes of cancer-related deaths. By offering a more accessible and non-invasive screening method, we aim to increase participation rates and improve outcomes, ultimately supporting a healthier future for the people of the UAE.”
Regular screening is the most effective strategy for preventing colorectal cancer and improving survival rates.
The Department of Health – Abu Dhabi recommends routine colorectal cancer screening for all men and women over the age of 40.
Colorectal cancer is the third most common cancer type in Abu Dhabi, with a higher incidence in males.
Data from 2023 reveals that 67 percent of new colorectal cancer cases in Abu Dhabi were diagnosed at a late stage, which adversely affects health outcomes and lowers survival rates.
The introduction of the liquid biopsy test represents a significant step forward in improving screening participation, early detection, and outcomes for the community.
